Extract

Funding sources: This study was supported by FCT (POCI/SAU – OBS/58600/2004) and FEDER, by CITS (01/09/CITS/CESPU) and UID/Multi/0437/2013.

Conflicts of interest: none declared.

Dear Editor, Psoriasis, a recurrent inflammatory skin condition, has been associated with metabolic syndrome (MS) and obesity. In psoriasis, obesity is closely related to hypoadiponectinaemia and hyperleptinaemia.1 High body mass index (BMI) adversely influences psoriasis therapy.2

C‐reactive protein (CRP), a marker of psoriasis severity,3 and Psoriasis Area and Severity Index (PASI) are determinants of the length of psoriasis remission.4 CRP and pentraxin (PTX)3, independent inflammatory markers of cardiovascular disease (CVD) risk, remain high after successful treatment.5

T helper (Th)17 and interleukin (IL)‐17 signalling play crucial roles in psoriasis pathogenesis. Increased IL‐17‐ and Th17‐related cytokines in psoriasis6 have led to the proposal of therapeutic agents targeting IL‐17.

Considering the overlap of inflammatory features in obesity and psoriasis, and the association of both conditions with CVD, we wondered about the impact of MS risk factors in psoriasis. We evaluated the levels of IL‐17, inflammatory markers and adipokines before and after psoriasis treatment, in order to evaluate whether MS influences the response to treatment and the length of psoriasis remission.

You do not currently have access to this article.